CN108495861B - 纤维化治疗 - Google Patents

纤维化治疗 Download PDF

Info

Publication number
CN108495861B
CN108495861B CN201680074600.XA CN201680074600A CN108495861B CN 108495861 B CN108495861 B CN 108495861B CN 201680074600 A CN201680074600 A CN 201680074600A CN 108495861 B CN108495861 B CN 108495861B
Authority
CN
China
Prior art keywords
fibrosis
expression
fibroblasts
antibody
tgfβ1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680074600.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN108495861A (zh
Inventor
斯图尔特·亚历山大·库克
塞巴斯蒂安·谢弗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National University of Singapore
Singapore Health Services Pte Ltd
Original Assignee
National University of Singapore
Singapore Health Services Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55274842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108495861(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by National University of Singapore, Singapore Health Services Pte Ltd filed Critical National University of Singapore
Priority to CN202310056618.9A priority Critical patent/CN116036284A/zh
Publication of CN108495861A publication Critical patent/CN108495861A/zh
Application granted granted Critical
Publication of CN108495861B publication Critical patent/CN108495861B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680074600.XA 2015-12-16 2016-12-16 纤维化治疗 Active CN108495861B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310056618.9A CN116036284A (zh) 2015-12-16 2016-12-16 纤维化治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1522186.4A GB201522186D0 (en) 2015-12-16 2015-12-16 Treatment of fibrosis
GB1522186.4 2015-12-16
PCT/EP2016/081430 WO2017103108A1 (en) 2015-12-16 2016-12-16 Treatment of fibrosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310056618.9A Division CN116036284A (zh) 2015-12-16 2016-12-16 纤维化治疗

Publications (2)

Publication Number Publication Date
CN108495861A CN108495861A (zh) 2018-09-04
CN108495861B true CN108495861B (zh) 2023-01-10

Family

ID=55274842

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680074600.XA Active CN108495861B (zh) 2015-12-16 2016-12-16 纤维化治疗
CN202310056618.9A Pending CN116036284A (zh) 2015-12-16 2016-12-16 纤维化治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310056618.9A Pending CN116036284A (zh) 2015-12-16 2016-12-16 纤维化治疗

Country Status (24)

Country Link
US (16) US10035852B2 (https=)
EP (7) EP3428187A1 (https=)
JP (2) JP6753933B2 (https=)
KR (2) KR102720360B1 (https=)
CN (2) CN108495861B (https=)
AU (7) AU2016369407B2 (https=)
CA (1) CA3007750A1 (https=)
CY (1) CY1120950T1 (https=)
DK (1) DK3298040T3 (https=)
ES (1) ES2692773T3 (https=)
GB (1) GB201522186D0 (https=)
HR (1) HRP20181692T1 (https=)
HU (1) HUE041433T2 (https=)
LT (1) LT3298040T (https=)
NZ (1) NZ744307A (https=)
PL (1) PL3298040T3 (https=)
PT (1) PT3298040T (https=)
RS (1) RS57894B1 (https=)
SG (2) SG11201804836RA (https=)
SI (1) SI3298040T1 (https=)
SM (1) SMT201800601T1 (https=)
TR (1) TR201815415T4 (https=)
WO (1) WO2017103108A1 (https=)
ZA (1) ZA201803727B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
AU2017378111A1 (en) * 2016-12-16 2019-06-13 National University Of Singapore IL-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201716733D0 (en) * 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809700D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
TWI858005B (zh) 2019-01-21 2024-10-11 新加坡商新加坡保健服務私人有限公司 肝毒性之治療
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
GB201906291D0 (en) 2019-05-03 2019-06-19 Singapore Health Serv Pte Ltd Treatment and prevention of metabolic diseases
CN114364693A (zh) 2019-05-03 2022-04-15 新加坡保健服务私人有限公司 代谢性疾病的治疗和预防
WO2021024170A1 (en) * 2019-08-05 2021-02-11 Voloshin Sela Tali Increasing cancer cells' sensitivity to tumor treating fields (ttfields) by inhibiting il11 activity
KR102270700B1 (ko) * 2019-11-01 2021-06-30 한국과학기술연구원 폐 섬유증의 예방 또는 치료를 위한 올리고뉴클레오티드 중합체와 생체 적합성 양이온성 펩타이드로 이루어지는 폐 특이적 약물 전달체 및 이의 이용
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
WO2022033538A1 (zh) * 2020-08-13 2022-02-17 广东东阳光药业有限公司 Il-11的抗体及其应用
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
MX2023009946A (es) 2021-02-26 2023-09-04 Bayer Ag Inhibidores de il-11 o il-11ra para uso en el tratamiento de sangrado uterino anormal.
US20250092126A1 (en) 2021-07-26 2025-03-20 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
KR20240067079A (ko) 2021-08-30 2024-05-16 라센 테라퓨틱스 1, 인코포레이티드 항-IL-11Rα 항체
CN115068442A (zh) * 2021-09-13 2022-09-20 荣灿生物医药技术(上海)有限公司 核酸的纳米颗粒组合物、其制备方法和用途
US20250082608A1 (en) 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
CN115414346B (zh) * 2022-08-29 2023-09-29 湖南复瑞生物医药技术有限责任公司 一种应用胺碘酮构造肺纤维化模型的方法
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
EP4702047A1 (en) 2023-04-25 2026-03-04 VVB Bio Pte. Ltd. Anti il-11 antibody
CN120518761B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种结合il-11的抗体、其抗原结合片段及应用
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
CN117085137A (zh) * 2023-10-10 2023-11-21 上海交通大学医学院附属第九人民医院 Il-11抑制剂及其在抗瘢痕治疗中的应用
CN117964734B (zh) * 2024-03-04 2025-12-26 四川大学 一种重组人白介素-11突变体及其与化学分子偶联缀合物和其制备方法与应用
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995211A (zh) * 2013-02-07 2015-10-21 Csl有限公司 Il-11r结合蛋白及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0786469B1 (en) 1990-06-11 2006-03-01 Gilead Sciences, Inc. Methods of use of nucleic acid ligands
ES2275268T3 (es) 1994-12-22 2007-06-01 Genetics Institute, Llc Uso de un receptor de la interleuquina 11 humana.
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6126933A (en) 1995-06-27 2000-10-03 Genetics Institute Methods of treating inflammatory bowel diseases by administering IL-11
US5679339A (en) 1995-06-27 1997-10-21 Keith; James Method of using IL-11 for treating spondyloarthropies
US6540993B1 (en) 1995-06-27 2003-04-01 Wyeth Method of treating inflammatory bowel disease using a topical formulation of IL-11
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
GB9721961D0 (en) 1997-10-16 1997-12-17 Glaxo Group Ltd Novel molecules
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
US6953777B2 (en) 1999-03-11 2005-10-11 Genetics Indtitute LLC Use of interleukin-11 to prevent immune-mediated cytotoxicity
AU5756100A (en) * 1999-06-21 2001-01-09 Genetics Institute Inc. Treatment of fibrosis by antagonism of il-13 and il-13 receptor chains
CA2386270A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB0021668D0 (en) 2000-09-04 2000-10-18 Smithkline Beecham Plc New use
AU2002362088A1 (en) 2001-12-06 2003-06-23 Catholic University Method and composition for inducing weight loss
BR0314356A (pt) 2002-09-16 2005-07-19 Wyeth Corp Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
EP1709074A4 (en) 2003-12-16 2008-06-11 Commw Scient Ind Res Org CYTOKIN BINDING DOMAINS
WO2005070446A1 (en) 2004-01-15 2005-08-04 Scios Inc. Method for treating cardiac remodeling following myocardial injury
US20080300147A1 (en) 2004-03-26 2008-12-04 Nasser Chegini Detection and Treatment of Fibrotic Disorders
ATE399868T1 (de) 2004-08-27 2008-07-15 Conaris Res Inst Ag Optimierte nukleotidsequenzen die für sgp130 kodieren
BRPI0619476A2 (pt) 2005-12-05 2011-10-04 Wyeth Corp composições de interleucina-11 e métodos de uso
DK2035369T3 (da) 2006-07-05 2014-10-06 Fibrotech Therapeutics Pty Ltd Terapeutiske
US8361966B2 (en) * 2006-10-27 2013-01-29 Osaka University Use of interleukin-11 as therapeutic agent for heart disease
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
JP5330398B2 (ja) 2007-10-26 2013-10-30 シーエスエル、リミテッド サイトカインムテイン
US8182814B2 (en) * 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
KR101133769B1 (ko) 2011-04-18 2012-04-09 한국생명공학연구원 신규한 옥사졸리딘계 및 인돌계 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물
CN105497893B (zh) 2015-12-10 2019-02-01 黑龙江省科学院高技术研究院 IL-11单克隆抗体在抑制PI3K/Akt信号通路中的应用
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
RU2016125115A (ru) 2016-06-23 2017-12-28 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Терапевтическое антитело, специфичное к интерлейкину-11, ингибирующее сигналирование через его рецептор, и способ его использования для лечения пациентов
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
AU2017378111A1 (en) 2016-12-16 2019-06-13 National University Of Singapore IL-11 antibodies
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
RU2016151730A (ru) 2016-12-28 2018-06-29 Федеральное государственное бюджетное учреждение науки Институт биологического приборостроения с опытным производством Российской Академии наук (ИБП РАН) Антитела для лабораторной диагностики концентрации интерлейкина-11
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
NL2020093B1 (en) 2017-12-15 2019-06-25 Stahl Int B V Process for producing aqueous polyurethane dispersions in a continuous manner; apparatus suitable for performing such a process; and products obtained by said process
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995211A (zh) * 2013-02-07 2015-10-21 Csl有限公司 Il-11r结合蛋白及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Critical Role of Interleukin-11 in Isoflurane-mediated Protection against Ischemic Acute Kidney Injury in Mice;Ham Ahrom等;《ANESTHESIOLOGY》;20131231;第119卷(第6期);1389-1401 *
Therapeutic Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-11 Ameliorates Cardiac Fibrosis After Myocardial Infarction;Obana Masanori等;《CIRCULATION》;20100209;第121卷(第5期);684-691 *
白细胞介素11的细胞生物学作用及防治疾病的研究进展;方静等;《使用临床医学》;20051231;第6卷(第8期);150-152 *

Also Published As

Publication number Publication date
KR102720360B1 (ko) 2024-10-22
AU2018229482A1 (en) 2018-10-04
AU2018229484B9 (en) 2019-09-12
JP7102474B2 (ja) 2022-07-19
US10894826B2 (en) 2021-01-19
US10106603B2 (en) 2018-10-23
SMT201800601T1 (it) 2019-01-11
AU2018229485A1 (en) 2018-10-04
US10035852B2 (en) 2018-07-31
US11939374B2 (en) 2024-03-26
EP3431498A1 (en) 2019-01-23
JP2019502689A (ja) 2019-01-31
TR201815415T4 (tr) 2018-11-21
ZA201803727B (en) 2019-03-27
KR20180097645A (ko) 2018-08-31
JP6753933B2 (ja) 2020-09-09
AU2018229487A1 (en) 2018-10-04
US10870696B2 (en) 2020-12-22
SG10201908380TA (en) 2019-11-28
US20180265579A1 (en) 2018-09-20
US20180362636A1 (en) 2018-12-20
US20180362640A1 (en) 2018-12-20
US10927169B2 (en) 2021-02-23
JP2020189879A (ja) 2020-11-26
EP3428188A1 (en) 2019-01-16
US10865241B2 (en) 2020-12-15
PT3298040T (pt) 2018-11-13
ES2692773T3 (es) 2018-12-05
SG11201804836RA (en) 2018-07-30
PL3298040T3 (pl) 2019-07-31
US20180371078A1 (en) 2018-12-27
US20210188962A1 (en) 2021-06-24
US10865239B2 (en) 2020-12-15
US20240360211A1 (en) 2024-10-31
EP3428186A1 (en) 2019-01-16
SI3298040T1 (sl) 2019-01-31
US20190002553A1 (en) 2019-01-03
AU2018229484B2 (en) 2019-08-08
AU2016369407B2 (en) 2018-09-13
US20180362639A1 (en) 2018-12-20
US20180362633A1 (en) 2018-12-20
HRP20181692T1 (hr) 2018-12-14
GB201522186D0 (en) 2016-01-27
WO2017103108A1 (en) 2017-06-22
US20170174759A1 (en) 2017-06-22
RS57894B1 (sr) 2019-01-31
US10865240B2 (en) 2020-12-15
EP3431500A1 (en) 2019-01-23
AU2018229484A1 (en) 2018-10-04
US10889642B2 (en) 2021-01-12
EP3431499A1 (en) 2019-01-23
CY1120950T1 (el) 2019-12-11
DK3298040T3 (en) 2018-11-05
US10870697B2 (en) 2020-12-22
US20180362641A1 (en) 2018-12-20
US10894827B2 (en) 2021-01-19
CN116036284A (zh) 2023-05-02
LT3298040T (lt) 2018-12-10
AU2018229485B2 (en) 2019-08-08
EP3428187A1 (en) 2019-01-16
US20180362634A1 (en) 2018-12-20
AU2018229486B2 (en) 2019-08-08
AU2018229487B2 (en) 2019-08-08
KR20240152973A (ko) 2024-10-22
NZ744307A (en) 2019-03-29
CA3007750A1 (en) 2017-06-22
US10822405B2 (en) 2020-11-03
US20180362638A1 (en) 2018-12-20
HUE041433T2 (hu) 2019-05-28
US10894825B2 (en) 2021-01-19
AU2018229483B2 (en) 2019-08-08
CN108495861A (zh) 2018-09-04
AU2018229482B2 (en) 2019-08-08
AU2018229486A1 (en) 2018-10-04
AU2018229483A1 (en) 2018-10-04
EP3298040B1 (en) 2018-08-01
US20180362635A1 (en) 2018-12-20
US20180371077A1 (en) 2018-12-27
US10899832B2 (en) 2021-01-26
US20180362637A1 (en) 2018-12-20
AU2016369407A1 (en) 2018-08-02
EP3298040A1 (en) 2018-03-28
HK1254287A1 (zh) 2019-07-19

Similar Documents

Publication Publication Date Title
CN108495861B (zh) 纤维化治疗
HK1254287B (en) Treatment of fibrosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254287

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant